Journal of the Pancreas Open Access

  • ISSN: 1590-8577
  • Journal h-index: 79
  • Journal CiteScore: 29.12
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Abstract

Preclinical Research in Treatment of Pancreatic Cancer

Muhammad Wasif Saif, Evangelia Skoura, Konstantinos N Syrigos

Pancreatic adenocarcinoma is an aggressive type of malignancy and remains a treatment-refractory cancer. Because of thefew treatment options, understanding of the molecular mechanisms is necessary, for new drugs be developed againstmolecular targets. Two of the novel, promising regimens against molecular targets, NVP-BEZ235 and MSK-777, wereexamined in three preclinical studies performed in human pancreatic cell lines and mouse models and presented in the 2013 ASCO Annual Meeting. Two of the studies evaluated the role of NVP-BEZ235, an oral phosphatidylinositol-3-kinase (PI3K) inhibitor, in pancreatic cancer treatment, alone and in combination with nab-paclitaxel (Abstract #e15007) or gemcitabine (Abstract #e15070). The third study presents the effectiveness of the novel cell division cycle 7 (Cdc7) kinase inhibitor, MSK- 777 (Abstract #e15059). All studies demonstrated promising results and further investigation is ongoing.